Interview with Harry Flore, CEO, HAL Allergy Group
Our meetings frequently bring us here to the Leiden Bio Science Park, but more often than not, to meet with younger, up-and-coming companies. HAL Allergy, meanwhile, has a rich and…
Address: J.H. Oortweg 15-17
2333 CH Leiden,Netherlands
Tel: +31-88-1959 000
Web: http://www.hal-allergy.com/
HAL stands for ‘Haarlems Allergenen Laboratorium’, an originally Dutch company set up in Haarlem over 50 years ago. A lot has happened since then. HAL Allergy has grown into a company of international repute that operates in as many as 15 countries. Our products are supplied to major European countries, such as Germany, Austria, Italy, the Benelux, Spain and Greece.
We take more than a little pride in our leading role in the production of allergen extracts, both for therapeutic and diagnostic purposes. Our head office, which houses the development, production, quality control, clinical and registration departments, has a staff of approximately 180. HAL Allergy works intensively with its foreign branches and prominent research institutes, thus optimally combining knowledge and experience. Our aim is to continuously improve ways of diagnosing, treating and curing allergies.
Our meetings frequently bring us here to the Leiden Bio Science Park, but more often than not, to meet with younger, up-and-coming companies. HAL Allergy, meanwhile, has a rich and…
Leadership in today’s pharmaceutical industry is no longer defined solely by the strength of a pipeline, but by the ability to anticipate change, execute consistently and adapt at scale. As…
As Synthon celebrates its 35th anniversary, the Dutch-headquartered complex generics specialist is entering a new phase of its evolution in the pursuit of affordable medicines worldwide. Having accelerated growth over…
Andreas Schuil, Vice President & General Manager EMEA at Orchard Therapeutics, discusses the company’s gene therapy for metachromatic leukodystrophy, a devastating ultra-rare paediatric disease. He highlights challenges in access, pricing…
Jay Iyer, CEO of the Access to Medicine Foundation, warns that rising nationalism and “onshoring” risk dismantling decades of progress in global health. As geopolitical tensions reshape how drugs are…
A century after insulin’s discovery transformed Type 1 diabetes from fatal to manageable, access remains deeply unequal. Writing exclusively for PharmaBoardroom, Access to Medicine Foundation CEO Jayasree Iyer explores why…
Philip Scheltens, Professor of Neurology and Partner and Head of the EQT Life Sciences Dementia Fund, reflects on the journey from founding the world’s first dedicated neurodegeneration investment fund to…
Globally some 1.8 million children and young people (CYP) live with type 1 diabetes (T1D) and in low-and middle-income countries (LMICs) prevalence of the disease is on the rise. In…
The 2024 Access to Medicine Index, released today, highlights some of the key milestones reached by global pharma in fostering access to their medicines in low- and middle-income countries (LMICs).…
The global pharma industry is facing increased pressure to ensure lifesaving medications reach underserved populations. Drawing from a new Access to Medicine Foundation report, AMF Head of Research Claudia Martinez…
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
See our Cookie Privacy Policy Here
